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Background: Pulmonary hypertension (PH) is considered a clinically important feature of
Obesity-Hypoventilation Syndrome (OHS). We aimed to determine prevalence, characteristics
and severity of PH including associations with clinical outcomes after established non-invasive
positive pressure ventilation (NPPV).
Methods: In a prospective cross-sectional study, clinically stable OHS-patients (NPPV
duration  3 months) were consecutively assessed using echocardiography, serum markers
and right-heart catheterization (RHC). NPPV use was quantified via ventilator counters. Blood
gases, lung function, Epworth-Sleepiness Scale (ESS), sleep-quality, WHO-functional class
(WHO-FC), 6-min walk distance, and health-related quality of life (HRQL) via Severe Respira-
tory Insufficiency (SRI) questionnaire were assessed.
Results: Of 177 patients considered, 64 fulfilled inclusion criteria. Among these, 21 patients
(10 female/11 male; BMI 45 [40; 53] kg/m2, PaCO2 39.6 [37.8; 45.5] mmHg (median [quar-
tiles])) gave consent for RHC. Four patients (19%) had normal mean pulmonary artery pressure
(mPAP < 20 mmHg), 8 (38.1%) mPAP 20e24 mmHg and 9 (42.9%) manifest PH
(mPAP  25 mmHg), 3 of them with combined pre- and/or postcapillary PH. mPAP wast of Internal Medicine III, Division of Pulmonary and Respiratory Medicine, RoMed Clinical Center
83022 Rosenheim, Germany. Tel.: þ49 (0) 8031 365 7101; fax: þ49 (0) 8031 365 4830.
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2062 C.A. Kauppert et al.negatively correlated to NPPV use, vital capacity and lung diffusing capacity (p < 0.01 each),
and positively to BMI (p < 0.05). NPPV use and vital capacity independently predicted mPAP. In
patients with PH, ESS, WHO-FC, and some SRI-items were worse (p < 0.05 each) compared to
patients without PH. Multivariate analyses revealed mPAP as the only independent predictor of
the SRI-physical functioning domain.
Conclusions: Mild to moderate PH is frequent in patients with OHS despite NPPV, mPAP being
inversely related to NPPV adherence. PH is associated with impairments in daytime-sleepiness,
WHO-FC, HRQL and physical functioning.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Obesity and obesity-related diseases are increasing world-
wide [1]. The Obesity-Hypoventilation Syndrome (OHS) is
defined by a Body-Mass Index (BMI)  30 kg/m2 and daytime
arterial carbon dioxide tension (PaCO2)  45 mmHg, after
exclusion of other causes for alveolar hypoventilation
[2e5]. The prevalence of OHS has markedly increased and
is associated with a considerable hospitalization rate,
excess morbidity and mortality [6e9]. The established and
mainstay treatment is intermittent non-invasive positive
pressure ventilation (NPPV) [2,4,5], which is effective in
ameliorating blood gases, sleep quality, daytime vigilance
and quality of life [7,8,10e17].
Beyond the respiratory impairment, OHS is often asso-
ciated with metabolic and cardiovascular derangements
[5,18]. In particular, pulmonary hypertension (PH) and right
heart failure, are frequently found [3,19] and considered to
be associated with poorer outcome [2,5]. Surprisingly, data
on PH in OHS, are sparse. In OHS patients without NPPV,
PH as defined by a mean pulmonary artery pressure
(mPAP) > 20 mmHg was present in 17 of 29 (59%) patients
[3]. Recent data suggest that NPPV has the potential to
improve pulmonary haemodynamics [20]. However, these
findings were based on echocardiography only and not on
right-heart catheterization (RHC), which is required for
diagnosing PH [21]. Thus, the question of whether PH per-
sists to a significant degree following the use of home NPPV
has not been answered.
We therefore aimed to evaluate the characteristics,
prevalence and severity of PH in patients with OHS and
established NPPV by using standard procedures including
RHC and to investigate associations of PH with physiological
and clinical outcome measures.Methods
Patient recruitment
Within a prospective, cross-sectional design, consecutive
patients with suspected OHS, admitted to Donaustauf Hos-
pital, Germany, for a follow-up investigation of domiciliary
NPPV between March 2009 and June 2010 were screened.
Only clinically stable patients, successfully adapted to
NPPV  3 months before and meeting the diagnostic
criteria for OHS (BMI  30 kg/m2 and daytime awake
PaCO2  45 mmHg) prior to NPPV were included. Exclusioncriteria were: other causes for hypoventilation (relevant
obstructive ventilatory impairment (FEV1/FVC < 65% and
FEV1 < 60%), thoracic restrictive diseases, interstitial lung
diseases, or neuromuscular disorders); lung resection; other
conditions potentially leading to PH (e.g. connective tissue
disease, HIV-infection; left-heart failure, liver diseases,
pulmonary embolism, haematological disorders); and clinical
signs for acute infection.
Following the recommendations of the ethics commit-
tee, exclusion criteria for RHC were extended to oral an-
ticoagulants intake, unstable coronary artery disease,
significant ECG abnormalities or valve disorders. However,
patients could participate in the non-invasive part of the
study, i.e. without RHC. The study was approved by the
ethics committee of the University of Regensburg, Germany
(approval number 09/032). Prior to inclusion, written
informed consent was obtained.
Measurements
Anthropometrics, co-morbidities, medication, and smoking
status were recorded. Blood cell counts and amino-terminal
pro B-type natriuretic peptide (NT-proBNP) (Elecsys 2010,
Roche, Basel, Switzerland) and cardiac Troponin I (cTnI)
(TNI-Ultra, Siemens, Eschborn, Germany) were determined.
NPPV use (time on pressure) was assessed via the time
counters of the ventilators. In case of ventilator change or
attendances, the data were completed via the recordings
of patient’s provider. Moreover, ventilator usage since
NPPV initiation was assessed.
Spirometry, body plethysmography and lung diffusing
capacity for carbon monoxide (DLCO) were determined
according to European Respiratory Society (ERS) guide-
lines, using common reference values [22]. Inspiratory
mouth occlusion pressures were assessed as described
previously [23]. Six-minute walk distance (6-MWD) was
determined based on the statement of the American
Thoracic Society (ATS) [24] and compared to established
references [25].
Capillary blood gases were assessed during daytime,
while breathing room air, and during nocturnal NPPV.
Moreover, nocturnal transcutaneous carbon dioxide tension
(ptCO2) (SDMS, SenTec, Therwil, Switzerland), mean
nocturnal oxygen saturation (SO2) and the respiratory
disturbance index (RDI) (Embletta, Thornton, USA), ac-
cording to the American Academy of Sleep Medicine
(AASM), using the alternative definition B to score hypo-
pnoea [26], were determined.
Figure 1 Patients’ recruitment.Among177 screenedpatients,
64 met inclusion criteria. 21 of them agreed in RHC. * as defined
by FEV1/FVC < 65% and FEV1 < 60% predicted. Definition of ab-
breviations: OHS Z Obesity-hypoventilation syndrome;
NPPVZNon-invasive positive pressure ventilation; RHCZ Right-
heart catheterization; PHZ Pulmonary hypertension.
Pulmonary hypertension in OHS 2063Additionally, WHO-Functional Class (WHO-FC) [21],
daytime sleepiness (Epworth Sleepiness-Scale (ESS)) [27],
and sleep quality (Pittsburgh Sleep-Quality-Index (PSQI))
[28] were assessed. Health-related quality of life (HRQL)
was quantified by the Severe Respiratory Insufficiency
questionnaire (SRI) [29].Table 1 Pulmonary haemodynamics assessed by right heart cat
Parameter No PH Borde
n (%) 4 (19%) 8 (38%
sPAP (mmHg) 24 [21; 28] 30 [30
dPAP (mmHg) 15 [13; 16] 15 [13
mPAP (mmHg) 18 [15; 19] 22 [22
PCWP (mmHg) 6 [5; 9] 9 [8;
TPG (mmHg) 10 [8; 13] 14 [12
RAP (mmHg) 3.5 [1.5; 8] 5.5 [4
CO (l/min) 8.5 [7.7; 9.0] 6.6 [5
CI (l/min/m2) 3.6 [3.2; 4.3] 2.9 [2
PVR (dyn s cm5) 96 [68; 126] 176 [1
PVRI (dyn s m2 cm5) 224 [148; 305] 392 [2
SvO2 (%) 74 [71; 76] 70 [69
Definition of abbreviations: sPAP Z Systolic pulmonary artery pressu
pulmonary artery pressure; PCWPZ Pulmonary capillary wedge pressu
pressure; COZ Cardiac output; CIZ Cardiac index; PVRZ Pulmonary
SvO2 Z Mixed venous oxygen saturation.Echocardiography
For assessment of the right ventricle, ventricle diameter, wall
thickness and tricuspidal annular plane systolic excursion
(TAPSE) were measured [30]. Systolic pulmonary artery pres-
sure (sPAP) was estimated from the tricuspidal regurgitation
jet velocity [30]. Left ventricular systolic function was
assessed by planimetric ejection fraction, and diastolic
function by mitral flow propagation velocity [31].Right-heart catheterization
RHC was performed at rest via the right internal jugular or
brachial vein without oxygen supply using a 7-F, 4-lumen
swan-ganz balloon catheter. Right atrial, right ventricular,
systolic, diastolic and mean pulmonary artery (mPAP), and
pulmonary capillary wedge (PCWP) pressures were recor-
ded computer-assisted. Cardiac output was determined by
thermodilution, averaging over 5 consecutive measure-
ments. Diagnosis and classification of PH followed
current guidelines [21]: no PH (mPAP  20 mmHg),
“borderline”-PH (mPAP 21e24 mmHg), or manifest PH
(mPAP  25 mmHg).Statistical analysis
Due to non-parametric data distributions, data are shown
as median (quartiles). The ManneWhitney-test was used for
group comparisons of continuous variables, and Fisher’s
exact test for categorical variables. The Spearman’s rank
correlation coefficient was employed to describe correla-
tions. To identify independent predictors, multivariate
linear regression analyses were used, keeping those vari-
ables that were significant in univariate analyses or path-
ophysiologically sensible. Parameters included in the
multivariate regression analysis were also tested for co-
linearity. A p-value < 0.05 was considered statistically
significant.heterization.
rline-PH PH All
) 9 (43%) 21 (100%)
; 33] 44 [38; 50] 34 [30; 44]
; 17] 24 [20; 26] 17 [14; 23]
; 23] 33 [29; 34] 23 [21; 30]
10] 14 [12; 16] 10 [8; 13]
; 16] 19 [15; 25] 14 [12; 18]
.5; 7.0] 11 [8.0; 12] 8.0 [5.0; 11]
.6; 7.5] 6.3 [5.8; 7.2] 7.0 [5.9; 7.9]
.5; 3.6] 2.9 [2.7; 3.1] 3.0 [2.7; 3.4]
16; 222] 189 [144; 366] 171 [116; 233]
87; 485] 440 [384; 728] 384 [267; 495]
; 71] 70 [68; 71] 70 [69; 72]
re; dPAP Z Diastolic pulmonary artery pressure; mPAP Z Mean
re; TPGZ Transpulmonary pressure gradient; RAPZ Right atrial
vascular resistance; PVRIZ Pulmonary vascular resistance index;
Table 2a Patients’ characteristics according to presence of PH.
Parameter No PH PH p-Valuea Correlation with mPAP
(p-value)b
Gender (female/male) 5/7 5/4 0.67 e
Age (years) 66.6 [59.0; 73.1] 59.4 [48.1; 62.8] 0.10 0.23 (0.32)
BMI (kg/m2) 41.5 [39.1; 48.2] 50.4 [44.7; 56.8] 0.033 0.46 (0.036)
Smoking duration (py) 20 [0; 32.5] 32 [0; 40] 0.35 0.14 (0.54)
Hb (g/dl) 13.9 [13.5; 14.9] 13.4 [12.8; 14.1] 0.36 0.21 (0.36)
NT-proBNP (pg/ml) 158 [96; 235] 224 [82.6; 312] 0.62 0.27 (0.26)
Troponin I (pg/ml) 9 [0; 18] 0 [0; 10] 0.35 0.18 (0.44)
VC (% predicted) 95.0 [81.1; 101.5] 82.2 [71.9; 90.9] 0.065 L0.56 (0.009)
FEV1 (% predicted) 85.5 [67.8; 95.5] 75.0 [63.8; 78.3] 0.126 L0.497 (0.022)
FEV1/VC (%) 77.3 [70.5; 80.9] 80.6 [75.0; 85.6] 0.320 0.260 (0.254)
DLCO (% predicted) 82.2 [77.3; 84.9] 68.7 [65.4; 72.2] 0.044 L0.66 (0.002)
P0.1 (% predicted) 116.4 [77.6; 133.2] 109 [89.8; 122] 0.72 0.21 (0.036)
PImax (% predicted) 48.7 [35.8; 73.8] 55.3 [41.1; 70.8] 0.89 0.07 (0.75)
pH daytime, room air 7.43 [7.41; 7.44] 7.42 [7.42; 7.45] 0.94 0.096 (0.68)
pO2 daytime, room air (mmHg) 62.4 [56.5; 65.6] 59.1 [58.1; 63.3] 0.55 0.27 (0.23)
PCO2 daytime, room air (mmHg) 40.4 [35.2; 44.5] 39 [37.8; 45.5] 0.83 0.18 (0.44)
pH nocturnal, NPPV 7.42 [7.40; 7.44] 7.42 [7.41; 7.43] 0.48 0.083 (0.72)
pO2 nocturnal, NPPV (mmHg) 71.4 [63.4; 95.4] 71.3 [64.4; 81.9] 0.86 0.18 (0.43)
PCO2 nocturnal, NPPV (mmHg) 41.5 [37.7; 46.5] 42.9 [40.5; 45.1] 0.50 0.14 (0.54)
Mean SO2 (%) 92 [91; 96] 93 [92; 96] 0.36 0.089 (0.70)
Mean ptCO2 (mmHg) 42.4 [38.1; 45.7] 43.1 [42.0; 44.9] 0.56 0.23 (0.32)
RDI (1/h) 3.3 [2.2; 7.3] 1.2 [0.6; 4.4] 0.48 026 (0.25)
Duration of NPPV (yr) 4.1 [0.7; 7.4] 1.6 [0.8; 1.9] 0.65 0.29 (0.20)
Daily NPPV use (h) 7.4 [5.9; 8.4] 5.1 [3.4; 6.6.] 0.019 L0.59 (0.005)
O2 supply, nocturnal 6 (50%) 7 (77%) 0.367 e
O2 supply, daytime 4 (33%) 5 (56%) 0.396 e
Data are shown as number (%) or median [quartiles].
Definition of abbreviations: BMIZ Body-mass index; HbZ Haemoglobin; NT-proBNPZ Amino-terminal pro B-type natriuretic peptide;
VCZ Vital capacity; FEV1Z Forced expiratory volume in 1 s; DLCOZ Diffusion capacity for carbon monoxide; P0.1Z Inspiratory mouth
occlusion pressure at 100 ms; pO2 Z Oxygen tension; PImax Z Maximum inspiratory pressure; PCO2 Z Carbon dioxide tension;
NPPV Z Non-invasive positive pressure ventilation; SO2Z Pulse oxygen saturation (nocturnal, NPPV); ptCO2 Z Transcutaneous carbon
dioxide tension (nocturnal, NPPV); RDI Z Respiratory disturbance index; PH Z Pulmonary hypertension.
Significant differences are marked in bold.
a p-Value for comparison between no PH vs. PH group.
b p-Value for correlation with mPAP by Spearman’s rho.
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Study population
Overall, 177 patients were considered to have OHS. Among
these, 113 were excluded (Fig. 1). Among the remaining 64
patients, 21 (10 female/11 male; BMI 45 [40; 53] kg/m2,
PaCO2 39.6 [37.8; 45.5] mmHg) gave consent for RHC. These
patients showed no relevant differences in their disease
characteristics compared to those refusing RHC with regard
to all parameters listed in Table 2a (age, gender, BMI,
smoking duration, laboratory values, lung function param-
eters including diffusion capacity, mouth occlusion pres-
sures, blood gas values during daytime and during NPPV,
mean SO2, mean ptCO2, RDI, daily use of NPPV, oxygen
supplementation (nocturnal, daytime)), and in Table 2b
(comorbidities and medication). Prior to inclusion, pa-
tients had been treated with NPPV for 1.9 [0.8; 4.4] years.NPPV was used 6.7 [4.6; 7.7] h/day. Thirteen patients (62%)
were on supplemental nocturnal oxygen, while 9 patients
(43%) had LTOT during daytime.Pulmonary haemodynamics
The median value of mPAP was 23 [21; 30] mmHg. Four
(19%) patients showed normal mPAP, 8 (38%) borderline-PH,
and 9 (43%) manifest PH (Table 1). Three of 9 patients
with PH, but none of the other two groups, had a
PCWP > 15 mmHg, suggesting a postcapillary component of
PH. As two of these 3 patients showed a transpulmonary
pressure gradient (TPG) > 12 mmHg (15 and 29 mmHg
respectively), but low PCWP (18 mmHg each), they had
combined pre- and postcapillary PH. The remaining patient
with elevated PCWP had pure postcapillary, mild PH (mPAP
25 mmHg).
Table 2b Main comorbidities and medication according to
presence of PH.
No PH PH p-Valueb
Comorbidity
Systemic hypertension 12 (100%) 9/12 (100%) 1.00
Diabetes 6 (50%) 8 (89%) 0.16
Hyperlipidaemia 6 (50%) 7 (79%) 0.37
Hyperuricemia 5 (42%) 3 (33%) 1.00
Chronic renal failurec 6 (50%) 2 (22%) 0.37
Coronary artery disease 2 (17%) 1 (11%) 1.00
Depression 2 (17%) 0 (0%) 0.49
Smoking history 8 (67%) 6 (67%) 1.00
Medication
ACE inhibitors 10 (83%) 5 (56%) 0.33
AT1 receptor antagonists 2 (17%) 1 (11%) 1.00
b-Blocker 6 (50%) 5 (56%) 1.00
Ca-channel antagonists 3 (25%) 2 (22%) 1.00
Diuretics 12 (100%) 8 (89%) 0.43
Bronchodilator agents 3 (25%) 3 (33%) 1.00
Acetylsalicylic acid 3 (25%) 1 (11%) 0.60
Oral antidiabetics 5 (42%) 4 (44%) 1.00
Insulin 1 (8%) 2 (22%) 0.55
Lipid lowering agents 4 (33%) 3 (33%) 1.00
Allopurinol 5 (42%) 3 (33%) 1.00
Antidepressive agents 2 (17%) 0 (0%) 0.49
a Either short-/longacting, regular or as needed.
b Using Fisher’s exact test (exact significance, two-sided).
c Glomerular filtration rate < 60 ml/min/1.73 m2.
Figure 2 Relationship between mPAP and NPPV use. NPPV
use shows a negative correlation to mPAP (Spearman’s
rho Z 0.59; p Z 0.005). Definition of abbreviations:
mPAP Z Mean pulmonary artery pressure; NPPV Z Non-inva-
sive positive pressure ventilation.
Pulmonary hypertension in OHS 2065Due to extreme obesity, the assessment of sPAP via tri-
cuspidal regurgitation jet velocity could be determined
with sufficient reliability in only 3 patients (14.2%).
Regarding the parameters that could be obtained in all
patients, TAPSE, E/A-ratio, and E-deceleration time were
not significantly different between patients without versus
borderline or manifest PH (data not shown).
Parameters associated with PH
Due to sample size, we only compared patients with versus
without PH, the latter including patients with borderline-
PH. Patients without or with manifest PH did not differ with
respect to age, sex, smoking status, daytime or nocturnal
blood gas values, mean nocturnal SO2, PtCO2, RDI and ox-
ygen supplementation (nocturnal, daytime) (Table 2a), as
well as comorbidities and medication (Table 2b). However,
the BMI of patients without PH was lower than those of
patients with manifest PH. Accordingly, BMI was positively
correlated to mPAP (rZ 0.46; pZ 0.036) (Table 2a). DLCO
was lower in patients with PH compared to those without
PH and inversely related to mPAP (r Z 0.66; p Z 0.002)
(Table 2a). Although vital capacity (VC)%predicted did not
statistically differ significantly between groups, overall it
was also inversely correlated to mPAP (r Z 0.56;
p Z 0.009). Daily NPPV use was lower in patients with PH
compared to patients without PH, and daily NPPV use was
inversely related to mPAP (rZ 0.059; pZ 0.006; Fig. 2).
In a multivariate linear regression analysis including BMI,
VC%predicted and daily NPPV use, only NPPV use(p Z 0.012) was an independent predictor of mPAP (Table
3). VC%predicted was also significant (p Z 0.045) when
the analysis was performed without BMI. When including
PaO2 or PaCO2 in the multivariate model, these parameters
were not significantly associated with mPAP. The same was
true when introducing the use of additional (nocturnal or
daytime) oxygen.
PH and clinical outcome
33% of patients with PH, but none of those without PH
showed pathological ESS > 10 (Fig. 3). Accordingly, scores
of patients with PH were significantly higher compared to
those of patients without PH. ESS-score was correlated with
mPAP (r Z 0.55; p Z 0.01) (Table 4).
SRI-SS was lower in patients with PH although this was
not statistically significant. However, the subitems “respi-
ratory complaints”, “physical functioning” and “psycho-
logical wellbeing” were significantly lower in patients with
PH compared to patients without PH (Table 4, Fig. 4).
Moreover, patients with PH had worse WHO-FC with a
higher proportion in Class II-III (p Z 0.019) compared to
patients without PH (Fig. 5). No significant differences were
found for sleep quality as measured by PSQI, or 6-MWD
(Table 4). In a multivariate linear regression analysis,
using VC%predicted, daily NPPV use and mPAP as explana-
tory variables, only mPAP was an independent predictor of
the SRI-physical functioning domain (Table 5).Discussion
This is the first study in patients with OHS and long-term
NPPV that invasively assessed pulmonary haemodynamics
and explored its clinical significance. The results suggest,
Table 3 Predictors of mPAP according to an adjusted linear regression analysis.
Variable b-Coefficient, standardized Regression coefficient (B) 95%-Confidence interval of (B) p-Value
BMI (kg/m2) 0.197 0.150 0.287; 0.682 0.40
VC (% predicted) 0.356 0.239 0.479; 0.001 0.051
NPPV use (h/d) 0.524 1.957 3.419; 0.496 0.012
For definition of abbreviations see Table 2.
Significant associations are marked in bold.
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is common, (2) PH severity is inversely related to the daily
NPPV use and linked to higher daytime sleepiness, (3) pa-
tients with PH presented with more impaired WHO-FC,
specific HRQL and subjective exercise capability.
Characteristics of PH in OHS
Although PH is considered a characteristic comorbidity of
OHS, data on its prevalence and severity under NPPV
therapy, assessed by RHC, have not yet been reported.
Kessler and coworkers [3] investigated 29 OHS-patients by
RHC, found 17 patients (59%) with an mPAP > 20 mmHg. In
our population, an mPAP > 20 mmHg was more frequent
(81%). However, unlike this former study, our patients were
treated by NPPV [3]. As NPPV can improve pulmonary
haemodynamics [20,32,33] it might be concluded that our
patients had more severe OHS. Actually, our patientsFigure 3 Daytime sleepiness measured by ESS according to
presence of PH. ESS-scores of PH group were significantly
higher than those without PH. Definition of abbreviations:
ESS Z Epworth sleepiness scale; PH Z Pulmonary
hypertension.presented with a higher BMI (45 [40; 53] vs. 40  8 kg/m2),
and pO2 and PCO2 prior NPPV were more impaired (data not
shown). Accordingly, BMI and vital capacity were correlated
with mPAP, while the well-known impact of hypercapnia
and hypoxaemia on PH [34,35] was presumably masked by
the NPPV treatment and/or LTOT.
In an earlier study of OHS-patients undergoing bariatric
surgery but not NPPV, mPAP > 20 mmHg was observed in 23
of 26 patients (88%) prior to surgery [19]. Although hae-
modynamics improved postoperatively, 55% of patients
studied still had PH. Preoperative mPAP was higher
(36  14 mmHg) than in our patients, while postoperatively
it was similar (23  7 mmHg). Nevertheless, the compara-
bility with our data is limited as a different definition of
OHS was used and neither BMI nor further details on the
population were reported. Specifically, the proportion of
postcapillary PH (54%) was higher than in our study in which
only three patients showed a PCWP > 15 mmHg. As obesity
often is linked to systolic or diastolic heart failure [34,36],
the low frequency of postcapillary PH in our population is
rather surprising. However, according to the study proto-
col, 6 patients with known left-heart failure or intake of
anticoagulants were a priori excluded. Pure postcapillary
PH was found only in one patient, while two patients
showed a pre- and postcapillary component.
Overall, PH was mostly mild to moderate. Only two pa-
tients fulfilled the criteria for severe PH (mPAP > 35 mmHg,
or mPAP  25 mmHg and CI < 2.0 l/min/m2, or
PVR > 480 dyn s cm5) [37]. Interestingly, the average NPPV
use of these two patients was rather low (1.9 and 0.3 h/d),
in line with the result that NPPV use was inversely related
to mPAP (Fig. 2) and even constituted an independent
predictor of mPAP (Table 3). Although these findings do not
allow to postulate causal relationships, they support the
view that NPPV has an effect on PH as indicated by non-
invasive measurements [20,32] or as observed in thoracic
restrictive diseases [33]. Conversely, chronic hypoxia, hy-
percapnia and acidosis may play a major role in the
development of PH in OHS [21,34], while clear-cut effects
of NPPV on daytime and nocturnal gas exchange have
been demonstrated [8,10,11,15e17,38,39]. Additionally,
obstructive sleep apnoea being highly prevalent in OHS is
presumably involved in the development of PH [40]. How-
ever, since PH was still present in some patients despite
regular use of NPPV, PH might persist to a relevant degree,
probably due to irreversible vascular remodelling or endo-
thelial dysfunction even after amelioration of nocturnal gas
exchange [41]. Surprisingly, PaO2 or current LTOT was not
significantly different between patients with/without PH.
However, the role of PaO2 for PH was potentially
Table 4 Subjective and functional measures according to presence of PH.
Parameter No PH PH p-Valuea Correlation with mPAP (p-value)b
ESS 3.5 [1.3; 6.0] 7 [6; 11] 0.010 0.55 (0.010)
PSQI 4.5 [2.3; 8.3] 7 [6; 11] 0.35 0.19 (0.42)
SRI-RC 86 [83; 98] 78 [69; 78] 0.001 L0.59 (0.005)
SRI-PF 81 [68; 95] 54 [42; 63] 0.005 L0.56 (0.008)
SRI-AS 73 [61; 88]a 71 [68; 75] 0.72 0.27 (0.24)
SRI-WB 88 [78; 97] 59 [51; 78] 0.011 L0.51 (0.017
SRI-SR 88 [68; 100] 79 [63; 92] 0.33 0.13 (0.59)
SRI-AX 95 [73; 99] 70 [65; 85] 0.12 0.13 (0.57)
SRI-SF 84 [66; 95] 78 [47; 86] 0.18 0.21 (0.36)
SRI-SS 82 [72; 93] 71 [65; 78] 0.055 0.30 (0.18)
6-MWD (%)c 89.0 [64.8; 102.2] 74.7 [70.8; 82.1] 0.20 0.20 (0.40)
6-MWD (m) 357 [330; 441] 305 [276; 375] 0.20 0.27 (0.26)
Definition of abbreviations: ESS Z Epworth sleepiness scale; PSQI Z Pittsburgh sleep quality index; SRI Z Severe respiratory insuffi-
ciency questionnaire; RC Z Respiratory complaints; PF Z Physical functioning; AS Z Attendant symptoms/sleep; WB Z Psychological
wellbeing; SR Z Social relationship; AX Z Anxiety; SF Z Social functioning; SS Z Summary score; 6-MWD Z 6-min walk distance;
PH Z Pulmonary hypertension.
Significant differences are marked in bold.
a p-Value for comparison between no PH vs. PH group.
b p-Value for correlation with mPAP by Spearman’s rho.
c According to the reference values of Enright and Sherrill. [25].
Pulmonary hypertension in OHS 2067underestimated as we could not objectively assess the
regular use of LTOT. The observation that VC was also
independently associated with mPAP (Tables 2a and 3) im-
plicates that the restrictive ventilatory impairment also
contributes to PH [34]. This detrimental effect of obesity
obviously is present more or less all the time despite NPPV.
Clinical impact of PH in OHS
PH is considered an unfavourable characteristic in many
chronic respiratory diseases [41], although most data relate
to COPD [42,43]. To elucidate the clinical consequences inFigure 4 Health-related quality of life (measured by SRI)
according to presence of PH. *p < 0.05 or **p < 0.01 value for
comparison of SRI-items. Definition of abbreviations:
SRI Z Severe respiratory insufficiency; RC Z Respiratory
complaints; PF Z Physical functioning; AS Z Attendant
symptoms/sleep; WB Z Psychological wellbeing; SR Z Social
relationship; AX Z Anxiety; SF Z Social functioning;
SS Z Summary scale; PH Z Pulmonary hypertension.OHS, we used a panel of established measures. Interest-
ingly, daytime sleepiness as determined by ESS was posi-
tively related to PH. With regard to the finding that daily
NPPV use was a strong predictor for PH, this appearedFigure 5 WHO-functional class according to presence of PH.
Patients with PH had a higher proportion in Class IIeIII
compared to patients without PH (Fisher’s exact test:
p Z 0.019). Definition of abbreviations: WHO-FC Z World
Health Organization-functional class; PH Z Pulmonary
hypertension.
Table 5 Predictors of the SRI-PF according to an adjusted linear regression analysis.
Variable b-Coefficient, standardized Regression coefficient (B) 95%-Confidence interval of (B) p-Value
VC (% predicted) 0.344 0.480 1.141; 0.181 0.14
NPPV use (h/d) 0.49 0.383 4.562; 3.795 0.85
mPAP (mmHg) 0.747 1.552 2.802; 0.302 0.018
For definition of abbreviations see Table 2.
Significant associations are marked in bold.
2068 C.A. Kauppert et al.plausible, reflecting the consistency of the data. PSQI
showed at least a trend towards worse sleep quality in PH,
although this association failed statistical significance.
Using WHO-FC as an established clinical marker to assess
severity and prognosis in PH [21], we found that, firstly,
patients with PH had worse WHO-FC and, secondly, all pa-
tients with PH scored WHO-FC II or higher (Fig. 5). The
median of 6-MWD was 52 m lower in patients with PH
compared to those without, but this difference was not
statistically significant, presumably due to the small the
numbers and the variation among patients. Moreover, in
line with previous observations [44], 6-MWD may be criti-
cally determined by severe obesity, thus inadequately
reflecting haemodynamics.
PH was best correlated with specific HRQL assessed by
the SRI which covers important domains and activities of
daily life and has been specifically developed for patients
receiving NPPV [29]. In patients with PH compared to those
without, 3 of 7 subitems were significantly lower. The
largest differences occurred in the subdomain “physical
functioning” (Fig. 4). To disentangle the role of PH from the
effect of regular NPPV use, which impacts HRQL per se
[9,45], we used multivariate regression analysis. This
revealed PH as an independent predictor of the SRI-physical
functioning domain.
Together, these findings indicate that PH affects
important clinical outcome measures, although its severity
was relatively low in most patients. Whether PH in OHS also
influences survival should be investigated in larger trials
taking into account the favourable prognosis of OHS pa-
tients undergoing NPPV [2]. As in COPD [46] or lung fibrosis
[47,48], however, even mild elevations of PAP could be
relevant for long-term outcome.Limitations
An obvious limitation is the small number of patients
studied invasively, although their characteristics were not
different from those refusing RHC. Moreover, the small
study population does not allow determining the preva-
lence of PH in OHS with sufficient reliability. In addition,
the limited power may explain why e.g. the differences of
NT-proBNP, as an established marker of PH [21], failed
statistical significance. According to protocol we strictly
excluded a priori patients showing potential causes for PH
other than OHS, such as pulmonary embolism, left-heart
failure or other lung diseases. However, we did not
extend the patients’ assessment according to the algorithm
for the detection of pulmonary arterial hypertension as
proposed by current guidelines [21], as we had reason toexpect that even more patients would have refused their
participation. Finally, echocardiography was limited by the
severe obesity and could be performed sufficiently only in
few patients, which was, however, in accordance with
previous observations [49].
In conclusion, mild to moderate PH is frequent in pa-
tients with OHS even in the presence of NPPV treatment.
Mean pulmonary artery pressure was inversely related to
the long-term use of NPPV and correspondingly to higher
daytime sleepiness. Moreover, PH was associated with
lower WHO-FC, specific HRQL and was an independent
predictor of SRI-physical functioning domain. Although the
role of PH for the long-term outcome of OHS is yet un-
known, PH should be considered in the regular clinical
assessment of these patients.Conflict of interests
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